2025
Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma.
Amer A, Ansari S, Krayyem A, Kundu S, Khose S, Pokhylevych H, Calle S, Patel C, Yang Z, Liu H, Johnson J. Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma. Journal Of Computer Assisted Tomography 2025 PMID: 39876523, DOI: 10.1097/rct.0000000000001716.Peer-Reviewed Original ResearchHigh-grade gliomasBlood-brain barrierDCE-MRIPeak contrast enhancementQuantify BBB permeabilityTreatment-related changesFollow-up subjectsKtrans mapsTrue progressionTumor progressionClinical dataConventional MRIPseudoprogressionBBB permeabilityCombined pathologyKtransContrast enhancementT1 enhancementStandard processing methodologyStatistically significant resultsClinical data setsPathologyPatientsGliomaSSS technique
2024
An update to the American Radium Society’s appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors
Tom M, Nagpal S, Palmer J, Breen W, Pollom E, Lehrer E, McGranahan T, Shiue K, Chundury A, McClelland Iii S, Saeed H, Chang E, Chiang V, Wang T, Knisely J, Chao S, Milano M. An update to the American Radium Society’s appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors. Radiotherapy And Oncology 2024, 202: 110640. PMID: 39557126, DOI: 10.1016/j.radonc.2024.110640.Peer-Reviewed Original ResearchA brave new framework for glioma drug development
Hotchkiss K, Karschnia P, Schreck K, Geurts M, Cloughesy T, Huse J, Duke E, Lathia J, Ashley D, Nduom E, Long G, Singh K, Chalmers A, Ahluwalia M, Heimberger A, Bagley S, Todo T, Verhaak R, Kelly P, Hervey-Jumper S, de Groot J, Patel A, Fecci P, Parney I, Wykes V, Watts C, Burns T, Sanai N, Preusser M, Tonn J, Drummond K, Platten M, Das S, Tanner K, Vogelbaum M, Weller M, Whittle J, Berger M, Khasraw M. A brave new framework for glioma drug development. The Lancet Oncology 2024, 25: e512-e519. PMID: 39362262, DOI: 10.1016/s1470-2045(24)00190-6.Peer-Reviewed Original ResearchConceptsBrain tumorsBenefits of biopsyBrain tumor therapyLiquid biopsy technologiesTissue samplesPostoperative deficitsBiopsy techniqueBiopsy technologyEffective therapySurgical trialsClinical trialsTumor therapyResistance mechanismsTumorTherapyPatientsDrug developmentTissue analysisBrainTrialsTissueBiopsyGliomaRegulatory agenciesImmune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function
Andrade A, Annett A, Karimi E, Topouza D, Rezanejad M, Liu Y, McNicholas M, Gonzalez Santiago E, Llivichuzhca-Loja D, Gehlhaar A, Jessa S, De Cola A, Chandarana B, Russo C, Faury D, Danieau G, Puligandla E, Wei Y, Zeinieh M, Wu Q, Hebert S, Juretic N, Nakada E, Krug B, Larouche V, Weil A, Dudley R, Karamchandani J, Agnihotri S, Quail D, Ellezam B, Konnikova L, Walsh L, Pathania M, Kleinman C, Jabado N. Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function. Nature Communications 2024, 15: 7769. PMID: 39237515, PMCID: PMC11377583, DOI: 10.1038/s41467-024-52096-w.Peer-Reviewed Original ResearchConceptsMyeloid populationsTumor microenvironmentExpression of immune checkpoint markersImmune checkpoint pathwaysImmune checkpoint markersSyngeneic mouse modelTumor-promoting functionsCheckpoint markersMyeloid infiltrationImmune landscapeImmune infiltrationImmune lineagesMyeloid cellsLymphoid cellsTumor cellsMouse modelTumor formationBenefit of patientsTherapeutic benefitBrain tumorsGliomaTumorDysregulated epigenomeDual inhibitionInfiltrationAutomated MR Spectroscopy single-voxel placement in suspected diffuse glioma based on tumor biology
Chadha S, Jacobs S, Zeevi T, Tillmanns N, Merkaj S, Lost J, Lin M, Bousabarah K, Holler W, Memon F, Aneja S, Aboian M. Automated MR Spectroscopy single-voxel placement in suspected diffuse glioma based on tumor biology. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2024 DOI: 10.58530/2024/5120.Peer-Reviewed Original ResearchTumor biologyDiffuse gliomasSingle-voxel magnetic resonance spectroscopyManagement of diffuse gliomasMagnetic resonance spectroscopyNon-invasive diagnosisVoxel placementMetabolite quantificationSingle-voxelMR imagingRadiology techniciansTumorGliomaPlacementResonance spectroscopyPoor-quality spectraClinicDiagnosisReevaluating the Role of T2/FLAIR Mismatch Sign: Improving Diagnostic Accuracy With Qualitative MRI Features?
Willms K, von Reppert M, Lost J, Tillmanns N, Merkaj S, Huttner A, Schrickel E, Memon F, Aboian M. Reevaluating the Role of T2/FLAIR Mismatch Sign: Improving Diagnostic Accuracy With Qualitative MRI Features? Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2024 DOI: 10.58530/2024/3586.Peer-Reviewed Original ResearchT2/FLAIR mismatch signIDH-mutant gliomasT2/FLAIR-mismatchVASARI featuresDiagnostic accuracyAccurate preoperative diagnosisIDH-mutant astrocytomasAccurate patient managementQualitative MRI featuresImproving diagnostic accuracyPreoperative diagnosisIDH-mutantImproved diagnostic toolsMRI featuresEnhanced diagnostic methodMismatch signGlioma subtypesPatient managementGlioma cohortGliomaNoninvasive methodDiagnostic precisionDiagnostic methodsDiagnostic toolAstrocytomaTumor-induced modifications of resting-state networks in patients with glioma
Pasquini L, Napolitano A, Schmid M, Jenabi M, Peck K, Holodny A. Tumor-induced modifications of resting-state networks in patients with glioma. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2024 DOI: 10.58530/2024/3149.Peer-Reviewed Original ResearchBrain networksHealthy controlsResting-state functional MRITumor locationResting-state networksFunctional MRIAssociated with tumor locationTumor boundariesCognitive disabilitiesTumor-induced alterationsCognitive networksBrainChi-square testTumor effectWHO-gradeFunctional alterationsEloquent areasTumor growthGlioma patientsWidespread effectsTumorPatient networksPatientsGliomaAlterationsComparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of BRAF V600E-Mutant Pediatric Gliomas in the Pacific Pediatric Neuro-Oncology Consortium Clinical Trial
Ramakrishnan D, Brüningk S, von Reppert M, Memon F, Maleki N, Aneja S, Kazerooni A, Nabavizadeh A, Lin M, Bousabarah K, Molinaro A, Nicolaides T, Prados M, Mueller S, Aboian M. Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of BRAF V600E-Mutant Pediatric Gliomas in the Pacific Pediatric Neuro-Oncology Consortium Clinical Trial. American Journal Of Neuroradiology 2024, 45: 475-482. PMID: 38453411, PMCID: PMC11288571, DOI: 10.3174/ajnr.a8189.Peer-Reviewed Original ResearchArea under the curvePediatric gliomasBT-RADSResponse assessmentPartial responseClinical trialsVolumetric analysisReceiver operating characteristic analysisBrain Tumor ReportingReceiver operating characteristic curveModel estimation timeOperating characteristic analysisEvaluate treatment efficacyStable diseasePartial respondersManual volumetric segmentationNo significant differenceSolid tumorsProspective studyTumor ReportingClinical decision-makingTreatment efficacyGliomaSignificant differenceCharacteristic curveTransmembrane pH gradient imaging in rodent glioma models
Mishra S, Santana J, Mihailovic J, Hyder F, Coman D. Transmembrane pH gradient imaging in rodent glioma models. NMR In Biomedicine 2024, 37: e5102. PMID: 38263680, PMCID: PMC10987279, DOI: 10.1002/nbm.5102.Peer-Reviewed Original ResearchNormal tissuesRodent glioma modelsGL261 gliomasU87 gliomasTumor microenvironmentPotential therapeutic targetGlioma modelTumor survivalExtracellular acidosisTumorMetabolic reprogrammingRegulate drug deliveryIntracellular pHRat brainExtracellular pHTherapeutic targetGliomaMouse brainDrug deliveryIntracellular milieuTransmembrane pH gradientBrainSubmillimeter resolutionTissueCells
2023
Imaging the transmembrane pH gradient in gliomas
Mishra S, Mihailović J, Hyder F, Coman D. Imaging the transmembrane pH gradient in gliomas. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/3928.Peer-Reviewed Original ResearchAssess tumor aggressivenessMonitoring treatment efficacyTransmembrane pH gradientTumor responseTumor microenvironmentTumor aggressivenessRG2 tumorsLocal drug deliveryExtracellular acidosisTherapeutic outcomesTumorTreatment efficacyNormal tissuesBrain tumorsIntracellular pHExtracellular pHFunction biomarkersPositive therapeutic outcomesDrug deliveryIntracellular milieuBrainAcidosisGliomaDeep learning-based groupwise registration for longitudinal MRI analysis in glioma
Hammecher C, van Garderen K, Smits M, Wesseling P, Westerman B, French P, Kouwenhoven M, Verhaak R, Vos F, Bron E, Li B. Deep learning-based groupwise registration for longitudinal MRI analysis in glioma. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/4361.Peer-Reviewed Original Research
2022
Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0
Piccardo A, Albert N, Borgwardt L, Fahey F, Hargrave D, Galldiks N, Jehanno N, Kurch L, Law I, Lim R, Lopci E, Marner L, Morana G, Young Poussaint T, Seghers V, Shulkin B, Warren K, Traub-Weidinger T, Zucchetta P. Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. European Journal Of Nuclear Medicine And Molecular Imaging 2022, 49: 3852-3869. PMID: 35536420, PMCID: PMC9399211, DOI: 10.1007/s00259-022-05817-6.Peer-Reviewed Original ResearchConceptsAmino acid positron emission tomographyPositron emission tomographyPaediatric neuro-oncologyEuropean Society for Paediatric Oncology (SIOPENeuro-oncologyLevel of evidenceBrain tumor groupPositron emission tomography imagingEvidence-based recommendationsPaediatric patientsTumor groupResponse assessmentClinician guidelinesPaediatric gliomasBrain gliomasImaging specialistsEmission tomographyRadiolabeled amino acidsConsensus opinionEANMPaediatric oncologyPET radiopharmaceuticalsGliomaNuclear medicineOncologyGraph theory demonstrates functional reorganization dynamics related to tumor grade and location in glioma
Pasquini L, Jenabi M, Peck K, Holodny A. Graph theory demonstrates functional reorganization dynamics related to tumor grade and location in glioma. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2022 DOI: 10.58530/2022/2564.Peer-Reviewed Original Research
2021
B2M overexpression correlates with malignancy and immune signatures in human gliomas
Zhang H, Cui B, Zhou Y, Wang X, Wu W, Wang Z, Dai Z, Cheng Q, Yang K. B2M overexpression correlates with malignancy and immune signatures in human gliomas. Scientific Reports 2021, 11: 5045. PMID: 33658560, PMCID: PMC7930032, DOI: 10.1038/s41598-021-84465-6.Peer-Reviewed Original ResearchMeSH Keywordsbeta 2-MicroglobulinBiomarkers, TumorBrain NeoplasmsCarcinogenesisCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticGenomicsGliomaHumansImmune Checkpoint ProteinsImmune ToleranceImmunotherapyIsocitrate DehydrogenaseKaplan-Meier EstimateMutationPrognosisPTEN PhosphohydrolaseTumor MicroenvironmentConceptsB2M expressionImmune signaturesM expressionB2MAssociated with immune checkpoint moleculesAssociated with PTEN deletionSuppress anti-tumor immunityAnti-tumor immunityImmune checkpoint moleculesImmunotherapy of gliomaLimited treatment strategiesStromal cell typesCheckpoint moleculesEGFR amplificationClinical characteristicsPTEN deletionPatient prognosisTumor progressionTreatment strategiesGenomic profilingInflammatory activityImmunotherapySomatic mutationsCGGA databasesGlioma
2020
Magnetic Resonance Imaging-Guided Focused Ultrasound-Based Delivery of Radiolabeled Copper Nanoclusters to Diffuse Intrinsic Pontine Glioma
Zhang X, Ye D, Yang L, Yue Y, Sultan D, Pacia C, Pang H, Detering L, Heo G, Luehmann H, Choksi A, Sethi A, Limbrick D, Becher O, Tai Y, Rubin J, Chen H, Liu Y. Magnetic Resonance Imaging-Guided Focused Ultrasound-Based Delivery of Radiolabeled Copper Nanoclusters to Diffuse Intrinsic Pontine Glioma. ACS Applied Nano Materials 2020, 3: 11129-11134. PMID: 34337344, PMCID: PMC8320805, DOI: 10.1021/acsanm.0c02297.Peer-Reviewed Original ResearchDiffuse intrinsic pontine gliomaBlood-brain tumor barrierIntrinsic pontine gliomaBlood-brain barrierPositron emission tomographyPontine gliomaBrainstem malignancyDelivery of therapeuticsTumor barrierWildtype miceEffective treatmentEmission tomographyFUS treatmentTumorDelivery efficiencyMiceFUS pressureGliomaTreatmentEffective deliveryDeliveryTime-dependent diffusionPET/CTMalignancyFUSClinical neuro-oncology for the neurologist.
Lukas R, Taylor J, Kurz S, Mohile N. Clinical neuro-oncology for the neurologist. Neurology Clinical Practice 2020, 10: 458-465. PMID: 33299675, PMCID: PMC7717629, DOI: 10.1212/cpj.0000000000000765.Peer-Reviewed Original ResearchNeuro-oncologyReclassification of tumorsClinical neuro-oncologyClinical practiceClinically relevant pointsCNS lymphomaNeuro-oncology patientsBrain metastasesInfiltrating gliomasBrain tumorsStandard managementAdult neurologistsTumorPatient carePatientsMolecular characteristicsEvolving fieldNeurologistsBrainLymphomaMetastasisMeningiomasGliomaCNSClinicPDIA3 correlates with clinical malignant features and immune signature in human gliomas
Zhang H, Zhou Y, Cheng Q, Dai Z, Wang Z, Liu F, Fan F, Cui B, Cao H. PDIA3 correlates with clinical malignant features and immune signature in human gliomas. Aging 2020, 12: 15392-15413. PMID: 32687065, PMCID: PMC7467394, DOI: 10.18632/aging.103601.Peer-Reviewed Original ResearchConceptsProtein disulfide isomerase family A member 3Suppression of anti-tumor immunityImmune checkpoint inhibitorsAnti-tumor immunityAmplification of EGFRLoss of PTENImmune regulatory processesAssociated with inflammationStromal cell typesCheckpoint inhibitorsTreatment of gliomaImmune signaturesTumor microenvironmentT cellsMalignant featuresImmune targetsGenomic profilingTherapeutic strategiesSomatic mutationsInvestigated expressionGliomaCGGA databasesHuman gliomasClinical practiceProcess of gliomaIn vivo MRS measurement of 2‐hydroxyglutarate in patient‐derived IDH‐mutant xenograft mouse models versus glioma patients
Tiwari V, Mashimo T, An Z, Vemireddy V, Piccirillo S, Askari P, Hulsey K, Zhang S, de Graaf R, Patel T, Pan E, Mickey B, Maher E, Bachoo R, Choi C. In vivo MRS measurement of 2‐hydroxyglutarate in patient‐derived IDH‐mutant xenograft mouse models versus glioma patients. Magnetic Resonance In Medicine 2020, 84: 1152-1160. PMID: 32003035, PMCID: PMC7263951, DOI: 10.1002/mrm.28183.Peer-Reviewed Original ResearchConceptsPatient-derived xenograftsPatient-derived xenograft micePreclinical modelsGlioma patientsPatient-derived xenograft tumorsPatient-derived xenograft modelsDetection of 2HGIDH1 R132H mutationShort-TE MRSXenograft mouse modelMutant gliomasR132H mutationIDH-mutantIn vivo MRS measurementsMouse modelPhantom analysisMetabolic reprogrammingPatientsMetabolite levelsGliomaMiceMetabolic fingerprintsPRESS sequenceIsocitrate dehydrogenaseMRS methodsExpression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes
Frenster J, Kader M, Kamen S, Sun J, Chiriboga L, Serrano J, Bready D, Golub D, Ravn-Boess N, Stephan G, S A, Kurz S, Jain R, Park C, Fenyo D, Liebscher I, Schöneberg T, Wiggin G, Newman R, Barnes M, Dickson J, MacNeil D, Huang X, Shohdy N, Snuderl M, Zagzag D, Placantonakis D. Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes. Neuro-Oncology Advances 2020, 2: vdaa053. PMID: 32642706, PMCID: PMC7262742, DOI: 10.1093/noajnl/vdaa053.Peer-Reviewed Original ResearchAdult gliomasIsocitrate dehydrogenase wild-type tumorsWild-type tumorsLimited treatment optionsBrain tissueNon-neoplastic brain tissuesTumor bulkAdvanced malignanciesGlioma familiesTumor specimensTumor marginsMutant gliomasAdult glioblastomaWHO gradeNovel therapiesTreatment optionsTumor growthGlioma subtypesBrain malignanciesTumorGliomaWild-typeIsocitrate dehydrogenaseMalignancyGlioblastoma
2019
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma
Spino M, Kurz S, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara C, Frenster J, Tateishi K, Wakimoto H, Jain R, Riina H, Nicolaides T, Sulman E, Cahill D, Golfinos J, Isse K, Saunders L, Zagzag D, Placantonakis D, Snuderl M, S. A. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma. Clinical Cancer Research 2019, 25: 1261-1271. PMID: 30397180, PMCID: PMC7365589, DOI: 10.1158/1078-0432.ccr-18-2312.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedBenzodiazepinonesBrainDNA MethylationFemaleGene Expression Regulation, NeoplasticGenotypeGliomaHumansImmunoconjugatesIntracellular Signaling Peptides and ProteinsIsocitrate DehydrogenaseLigandsMaleMembrane ProteinsMolecular Targeted TherapyMutationNeoplasm Recurrence, LocalReceptors, NotchRNAConceptsGlioma molecular subtypesAntibody-drug conjugatesMolecular subtypesCell surface tumor-associated antigensTumor-associated antigensWild-type glioblastomaAntigen-dependent mannerLow-grade gliomasRova-TRecurrent tumorsDLL3 expressionRovalpituzumab tesirineNontumor brain tissuesNontumor brainMutant gliomasTherapeutic strategiesCell viability assayGliomaRNA levelsDLL3TumorspheresTherapeutic targetIHCTCGA dataWild-type
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply